Non-Invasive Prenatal Testing Market (By Component: Instruments, Kits and Reagents, Services; By Application: Down Syndrome (trisomy 21), Edwards Syndrome (trisomy 18), Patau Syndrome (trisomy 13), Turner Syndrome, Other Applications; By End User: Hospitals, Diagnostic Labs) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Non-Invasive Prenatal Testing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Non-Invasive Prenatal Testing Market, by Component, 2024-2034
8.1.1 Instruments
8.1.1.1. Market Revenue and Forecast (2023-2034)
8.1.2. Kits and Reagents
8.1.2.1. Market Revenue and Forecast (2023-2034)
8.1.3. Services
8.1.3.1. Market Revenue and Forecast (2023-2034)
9.1. Non-Invasive Prenatal Testing Market, by Application, 2024-2034
9.1.1. Down Syndrome (trisomy 21)
9.1.1.1. Market Revenue and Forecast (2023-2034)
9.1.2. Edwards Syndrome (trisomy 18)
9.1.2.1. Market Revenue and Forecast (2023-2034)
9.1.3. Patau Syndrome (trisomy 13)
9.1.3.1. Market Revenue and Forecast (2023-2034)
9.1.4. Turner Syndrome
9.1.4.1. Market Revenue and Forecast (2023-2034)
9.1.5. Other Applications
9.1.5.1. Market Revenue and Forecast (2023-2034)
10.1. Non-Invasive Prenatal Testing Market, by End User, 2024-2034
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2023-2034)
10.1.2. Diagnostic Labs
10.1.2.1. Market Revenue and Forecast (2023-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Component (2023-2034)
11.1.2. Market Revenue and Forecast, by Application (2023-2034)
11.1.3. Market Revenue and Forecast, by End User (2023-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Component (2023-2034)
11.1.4.2. Market Revenue and Forecast, by Application (2023-2034)
11.1.4.3. Market Revenue and Forecast, by End User (2023-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Component (2023-2034)
11.1.5.2. Market Revenue and Forecast, by Application (2023-2034)
11.1.5.3. Market Revenue and Forecast, by End User (2023-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Component (2023-2034)
11.2.2. Market Revenue and Forecast, by Application (2023-2034)
11.2.3. Market Revenue and Forecast, by End User (2023-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Component (2023-2034)
11.2.4.2. Market Revenue and Forecast, by Application (2023-2034)
11.2.4.3. Market Revenue and Forecast, by End User (2023-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Component (2023-2034)
11.2.5.2. Market Revenue and Forecast, by Application (2023-2034)
11.2.5.3. Market Revenue and Forecast, by End User (2023-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Component (2023-2034)
11.2.6.2. Market Revenue and Forecast, by Application (2023-2034)
11.2.6.3. Market Revenue and Forecast, by End User (2023-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Component (2023-2034)
11.2.7.2. Market Revenue and Forecast, by Application (2023-2034)
11.2.7.3. Market Revenue and Forecast, by End User (2023-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Component (2023-2034)
11.3.2. Market Revenue and Forecast, by Application (2023-2034)
11.3.3. Market Revenue and Forecast, by End User (2023-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Component (2023-2034)
11.3.4.2. Market Revenue and Forecast, by Application (2023-2034)
11.3.4.3. Market Revenue and Forecast, by End User (2023-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Component (2023-2034)
11.3.5.2. Market Revenue and Forecast, by Application (2023-2034)
11.3.5.3. Market Revenue and Forecast, by End User (2023-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Component (2023-2034)
11.3.6.2. Market Revenue and Forecast, by Application (2023-2034)
11.3.6.3. Market Revenue and Forecast, by End User (2023-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Component (2023-2034)
11.3.7.2. Market Revenue and Forecast, by Application (2023-2034)
11.3.7.3. Market Revenue and Forecast, by End User (2023-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Component (2023-2034)
11.4.2. Market Revenue and Forecast, by Application (2023-2034)
11.4.3. Market Revenue and Forecast, by End User (2023-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Component (2023-2034)
11.4.4.2. Market Revenue and Forecast, by Application (2023-2034)
11.4.4.3. Market Revenue and Forecast, by End User (2023-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Component (2023-2034)
11.4.5.2. Market Revenue and Forecast, by Application (2023-2034)
11.4.5.3. Market Revenue and Forecast, by End User (2023-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Component (2023-2034)
11.4.6.2. Market Revenue and Forecast, by Application (2023-2034)
11.4.6.3. Market Revenue and Forecast, by End User (2023-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Component (2023-2034)
11.4.7.2. Market Revenue and Forecast, by Application (2023-2034)
11.4.7.3. Market Revenue and Forecast, by End User (2023-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Component (2023-2034)
11.5.2. Market Revenue and Forecast, by Application (2023-2034)
11.5.3. Market Revenue and Forecast, by End User (2023-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Component (2023-2034)
11.5.4.2. Market Revenue and Forecast, by Application (2023-2034)
11.5.4.3. Market Revenue and Forecast, by End User (2023-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Component (2023-2034)
11.5.5.2. Market Revenue and Forecast, by Application (2023-2034)
11.5.5.3. Market Revenue and Forecast, by End User (2023-2034)
12.1. Genesis Genetics (CooperSurgical, Inc.)
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Natera, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Centogene N.V.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Illumina, Inc. (Verinata Health, Inc.)
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Eurofins LifeCodexx GmbH
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. MedGenome Labs Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. F. Hoffmann-La Roche Ltd. (Ariosa Diagnostics)
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Myriad Women’s Health, Inc. (Counsyl, Inc.)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Progenity, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Qiagen
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample